Eltrombopag olamine is a new, orally active thrombopoietin-receptor (c-mpl) agonist that stimulates thrombopoiesis. American Society of Health-System Pharmacists, Inc., 4500 East-West Highway, Suite 900, Bethesda, Maryland 20814. If you need to change the delivery plan for items ordered, please contact us via email [emailprotected]. Adjust dosage in 25-mg increments every 2 weeks as necessary to achieve the target platelet count required to initiate antiviral therapy (see Table 7). PROMACTA . 2009 Feb;27(2):424-30. Metabolized by CYP1A2 and CYP2C8; also undergoes glucuronidation by UGT isoenzymes 1A1 and 1A3. Eltrombopag Olamine (17.6 mg/kg; IP; once a day for 2 days) significantly reduces mean S. aureus counts in mice nasal infection[3]. Chemical Name:Eltrombopag olamine. Promoted BAF3/hTpoR cells proliferation after incubated for 2 days with an EC, Dose-dependently stimulated the differentiation from bone marrow CD34, 0, 0.003, 0.01, 0.03, 0.1, 0.3, 1 and 3 M. Decreases in platelet counts generally observed within 12 weeks after discontinuance of therapy. Prepare the suspension only with water. Eltrombopag Olamine (Eltrombopag diethanolamine salt) is an orally active thrombopoietin receptor nonpeptide agonist. Asian ancestry (i.e., Japanese, Chinese, Taiwanese, Korean, or Thai) with ITP or chronic hepatitis C: plasma eltrombopag concentrations approximately 5055% higher compared with patients with non-Asian ancestry. UNII-4U07F515LG, Promacta, Revolade (ChemID). Outside CAS Common Chemistry. Brand name: Promacta. Exhibited dose-dependently antiapoptotic effects N2C-Tpo cells with a concentration over 0.03 M. Adjust dosage based on platelet count (see Table 6); manufacturer recommends that a platelet count 50,000/mm3 be achieved and maintained as necessary to reduce risk of bleeding. Discovery and characterization of a selective, nonpeptidyl thrombopoietin receptor agonist. Eltrombopag Olamine. Individualize treatment decisions and consider comparative risks and benefits, and adverse effects of therapy. TSA (Tyramide Signal Amplification), used for signal amplification of ISH, IHC and IC etc. It is taken by mouth. Metabolites associated with glucuronidation and oxidation detected. ITP is a condition in which platelets are destroyed by the immune system. Small-molecule thrombopoietin receptor agonist (TPO-RA). Preclinical activity of eltrombopag (SB-497115), an oral, nonpeptide thrombopoietin receptor agonist. Usual initial dosage is 50 mg once daily. . Risk of hepatobiliary laboratory abnormalities. Products with functional groups. Brand name: Promacta It has the molecular formula C 25 H 22 N 4 O 4 2(C 2 H 7 NO). Stem Cells. This material is provided for educational purposes only and is not intended for medical advice, diagnosis or treatment. Toggle Nav ChemBK. [Content Brief], [4]. Whereas romiplostim is a peptide which has to be injected, eltrombopag is a small non-peptide molecule which can be given orally. Designated an orphan drug by FDA for treatment of ITP. Macrophage migration inhibitory factor (MIF), Epithelial Cell Adhesion Molecule (EpCAM), Killer-Cell Immunoglobulin-Like Receptors, Cyclin-Dependent Kinase Inhibitor Proteins, Exosome Isolation, Purification and Detection, Anti-Cardiovascular Disease Compound Library, FDA Approved & Pharmacopeial Drug Library, Drug-Induced Liver Injury (DILI) Compound Library. The chemical name of the eltrombopag olamine is 3- { (2Z) -2- [1- (3,4- xylyls) -3- methyl -5- oxos -1,5- two Hydrogen -4H- pyrazoles -4- subunits] diazanyl } -2- hydroxyl -3- biphenyl acid. Stem Cells. Erickson-Miller CL, et al. If liver function tests abnormal, repeat tests within 35 days; if abnormalities persist, monitor liver function tests on a weekly basis until the abnormality resolves or stabilizes. Pediatric patients 1 year of age: Maximum 75 mg once daily. May cause fetal harm; embryolethality and reduced fetal weights reported in animal studies. 'Eltrombopag olamineis an antihemorrhagic dug. Promacta. Delist Requested. Eltrombopag Olamine also has highly inhibitory effects against multidrug resistant Staphylococcus aureus. Type of study: Fasting Design: Single-dose, two treatment, two-period, crossover in vivo . View cart. 22291. DrugBank Accession Number. Monitor liver function tests (e.g., ALT, AST, bilirubin) every 2 weeks during the dose adjustment phase and then monthly during establishment of a stable dosage; if any abnormalities are found, monitor serum liver function tests weekly until resolution or stabilization. For patients with Asian ancestry or hepatic impairment, reduce initial dosage to 25 mg once daily. Exp Hematol. . We do not sell or distribute actual drugs. C57BL/6 male mice (7 weeks, 20-22 g; injected, Significantly reduced mean bacterial counts (5.0 10. 2025C (excursions permitted to 1530C); dispense in original bottle. Eltrombopag Olamine purchased from MCE. MCE has not independently confirmed the accuracy of these methods. Eltrombopag Olamine can induce apoptosis in hepatocellular carcinomab (HCC) as well[1][2][3][4][5]. Eltrombopag (0-3 M; 72 h) affects N2C-Tpo cell apoptosis[1]. Total duration of therapy for first-line treatment of severe aplastic anemia is 6 months. We do not sell to patients. If platelet counts decrease to <30,000/mm3, hemoglobin decreases to <9 g/dL, or ANC decreases to <500/mm3, may reinitiate eltrombopag at the previous effective dosage. Substance Name: Eltrombopag olamine [USAN:JAN] RN: 496775-62-3 UNII: 4U07F515LG InChIKey: PLILLUUXAVKBPY-SBIAVEDLSA-N Note An oral, nonpeptide thrombopoietin receptor agonist. Stem Cells. Effectively inhibited murine BAF3 cells with human TpoR with an EC, 30 M for N2C-Tpo cells; 0, 1, 3 and 10 M for CD34, 120 min for N2C-Tpo cells; 30 min for CD34. Unchanged drug excreted in feces accounts for 20% of the dose; no unchanged drug detectable in urine. Antibiotics (Basel). Curr Microbiol. Inform patients that risks associated with long-term administration of eltrombopag are not known. Jigs chemical is global Manufacturer, supplier of Eltrombopag olamine,496775-62-3, industrial chemicals, solvents, exporters, Sourcing, Distributor, bulk, MSDS, specification & COA, documentation, as per requirements of RND/ Development or commercial quantities with best price Eltrombopag (0.1-100 g/mL; 72 h) exhibits anti-proliferative activity against HCC cell lines[5]. Adjust dosage of eltrombopag based on platelet counts (see Table 8). Molecular Weight. For patients with both Asian ancestry and hepatic impairment, consider initiating eltrombopag at a reduced dosage of 12.5 mg once daily. Pediatric patients 15 years of age: Initially, 25 mg once daily. We do not sell to patients. Perform ocular examinations during therapy. For research use only. Film-coated tablet. In patients with Asian ancestry or hepatic impairment, reduce initial dosage to 75 mg once daily. Thromboembolic events, including both venous and arterial events, observed even with normal or low platelet counts. Promacta, prednisone, dexamethasone, triamcinolone, Decadron, Deltasone, Kenalog-40, Nplate, Leukine, sargramostim. Data sources include IBM Watson Micromedex (updated 1 Nov 2022), Cerner Multum (updated 25 Oct 2022), ASHP (updated 12 Oct 2022) and others. Protect the integrity of proteins from multiple proteases and phosphatases for different applications. titanium grade 2 chemical composition; debugging techniques in embedded systems pdf; using mortar mix to repair concrete; list of rivers in maharashtra pdf; microfreak ultimate patches; gurusamipalayam pincode; good life veggie sausage; dizziness in pregnancy icd-10; lambda function urls are now available on aws; input type=date min/max not working Do not administer more than one dose in any 24-hour period. The Eltrombopag antitumor effect on hepatocellular carcinoma. [14C]Eltrombopag olamine (bismonoethanolamine salt, specific activity of 113 Ci/mg, radiochemical purity of 96%), unlabeled eltrombopag olamine (chemical purity of 99%), and a cleavage product of eltrombopag, SB-611855 (2'-hydroxy-3'-amino-3-biphenylcarboxylic acid), were all synthesized by Chemical Development, GlaxoSmithKline, UK. -5-methyl-3-oxo-1H-pyrazol-4-yl]hydrazinylidene]-6-oxocyclohexa-1,3-dien-1-yl]benzoic acid; Chemical & Physical . 496775-62-3. PROMACTA PROMACTA (eltrombopag) Tablets contain eltrombopag olamine, a small molecule thrombopoietin (TPO) receptor agonist for oral administration. *In solvent : -80C, 6 months; -20C, 1 month (sealed storage, away from moisture). Advise women to inform their clinicians if they are or plan to become pregnant or plan to breast-feed. For chemical emergency spill, leak, fire, exposure, or accident call CHEMTREC day or night: Within USA and Canada: 1-800-424-9300. Toggle Nav ChemBK. TREATMENT OF THROMBOCYTOPENIA IN PATIENTS WITH CHRONIC HEPATITIS C TO ALLOW THE INITIATION AND MAINTENANCE OF INTERFERON-BASED THERAPY. [1]. Cautiously reintroduce eltrombopag while monitoring liver function weekly during the dosage adjustment phase. Name: Eltrombopag olamine Synonym: More Synonyms Eltrombopag olamine Biological Activity. Food (standard high-fat breakfast) decreases rate and extent of absorption; calcium content of meal may contribute to decreased absorption. The chemical Eltrombopag olamine has a designated molecular formula of C29H36N6O6 and a molecular weight of 564.643 g/mol. . Eltrombopag is an orally bioavailable, small-molecule TPO-receptor agonist that interacts with the transmembrane domain of the human TPO-receptor. Discovery and characterization of a selective, nonpeptidyl thrombopoietin receptor agonist. Strength: EQ 75 . If serum bilirubin concentration is elevated, obtain a fractionated measurement. Eltrombopag is recognized as a first- and second-line treatment option for children and adults with aplastic anemia. In solution, store at -20C and use within 3 months to prevent loss of potency. ;In vitro: Eltrombopag demonstrated a half maximal effective concentration (EC50) of 0.27 uM in murine BAF3 cells transfected with the luciferase reporter gene under direction of the STAT-activated IRF-1 promoter and human TpoR (BAF3/IRF-1/hTpoR) [1]. Eltrombopag Diethanolamine salt. When used for first-line treatment of severe aplastic anemia, monitor ALT, AST, and bilirubin every other day while hospitalized for horse antithymocyte globulin (h-ATG) therapy, then every 2 weeks during treatment. Discard any remaining suspension if not administered within 30 minutes of preparation. VA class: BL400 1. Do not use hot water. Eltrombopag Class: Hematopoietic Agents ATC Class: B02BX05 VA Class: BL400 Chemical Name: 3- { (2Z)-2- [1- (3, 4-dimethylphenyl)-3-methyl-5-oxo-1, 5-dihydro-4H-pyrazol-4-ylidene] hydrazino}-2-hydroxy-3-biphenylcarboxylic acid-2-aminoethanol (1:2) Molecular Formula: C 25 H 22 N 4 O 4 2 (C 2 H 7 NO) CAS Number: 496775-62-3 Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% saline, Solubility: 2.08 mg/mL (3.68 mM); Clear solution, Add each solvent one by one: 10% DMSO 90% (20% SBE--CD in saline), COA (256 KB) In patients with ITP and hepatic impairment (Child-Pugh class A, B, or C), dosage should be increased no sooner than 3 weeks after initiation of eltrombopag or after any subsequent dosage increase. Polyvalent cations in food or supplements will be chelated by eltrombopag; therefore, they should be separated by 4 hours before or 2 hours after taking eltrombopag. Juan Zhu, et al. Peak plasma concentrations occur 26 hours following oral administration. Chemsrc provides Eltrombopag olamine(CAS#:496775-62-3) MSDS, density, melting point, boiling point, structure, formula, molecular weight etc. Chemical name: 3-{(2Z)-2-[1-(3, 4-dimethylphenyl)-3-methyl-5-oxo-1, 5-dihydro-4H-pyrazol-4-ylidene] hydrazino}-2-hydroxy-3-biphenylcarboxylic acid-2-aminoethanol (1:2) Each tablet. Synonyms: Eltrombopag diethanolamine salt; SB-497115GR Formula: C29H36N6O6 Molecular Weight: 564.63 CAS No. Eltrombopag olamine is a new, orally active thrombopoietin-receptor (c-mpl) agonist that stimulates thrombopoiesis. Qianyan Chemical Technology (Wuhan) Co., Ltd. Request for quotation. Antibiotics (Basel). Moderate (Child-Pugh class B) and severe hepatic impairment (Child-Pugh class C): Eltrombopag AUC is approximately 2-fold higher; half-life prolonged 2-fold. Patent Use Code. CAS Number. Eltrombopag Olamine owns thrombopoietic activity, and has been used to research low blood platelet counts with chronic immune thrombocytopenia. [Content Brief]. Generic Name. A3387 C-mpl agonist Skip to the end of the images gallery Skip to the beginning of the images gallery Tel: +1-832-696-8203 Email: sales@apexbt.com Worldwide Distributors Bulk Inquiry Add to Cart Check Out Background Chemical Properties Quality Control Background As the situation with COVID-19 continues to unfold in every community, MedChemExpress is responding to the uncertainty caused by this outbreak thoughtfully and cautiously. Risk of hepatic decompensation when eltrombopag is used in combination with interferon and ribavirin in patients with chronic hepatitis C. (See Boxed Warning.) Eltrombopag diethanolamine salt;Promacta;Revolade;SB-497115GR, insoluble in EtOH; insoluble in H2O; 14.12 mg/mL in DMSO with gentle warming, 2-aminoethanol;3-[(5E)-5-[[2-(3,4-dimethylphenyl)-5-methyl-3-oxo-1H-pyrazol-4-yl]hydrazinylidene]-6-oxocyclohexa-1,3-dien-1-yl]benzoic acid, CC1=C(C=C(C=C1)N2C(=O)C(=C(N2)C)NN=C3C=CC=C(C3=O)C4=CC(=CC=C4)C(=O)O)C.C(CO)N.C(CO)N. Ship with blue ice, or upon other requests. Patients with chronic hepatitis C and hepatic impairment have increased plasma concentrations and prolonged half-life of eltrombopag. We serve Chemical Name:Eltrombopag olamine CAS:496775-62-3 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. AUC of eltrombopag is increased in patients with Asian ancestry (i.e., Japanese, Chinese, Taiwanese, Korean, or Thai); dosage adjustments recommended. C25H22N4O4. We will send it to your Email address shortly. Search for free and find new suppliers for chemical products, pharmaceuticals and APIs. Subscribe to Drugs.com newsletters for the latest medication news, new drug approvals, alerts and updates. Chemical & Physical Properties. Eltrombopag olamine is indicated for the treatment of thrombocytopenia in patients with chronic immune (idiopathic) thrombocytopenia (ITP) who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy. Products (13) Write a Review; Company View; Product View; Your search . Eltrombopag olamine is used in certain patients with ITP who have not gotten better with other treatment. Identification of Eltrombopag as a Repurposing Drug Against Staphylococcus epidermidis and its Biofilms. Contact China Trader ROYAL PHARM for the product Eltrombopag Olamine CAS No.496775-62-3. Eltrombopag olamine is prepared from salts of eltrombopag, which are used as intermediates. Kurokawa T, et al. DB06210. 496775-61-2. Identification of Eltrombopag as a Repurposing Drug Against Staphylococcus epidermidis and its Biofilms. Phone. Dyes, stains, or substrates may also be specified by name. Substrates of OATP1B1 or BCRP: Potential pharmacokinetic interaction (increased concentrations) of concomitantly administered OATP1B1 substrates (e.g., atorvastatin, bosentan, ezetimibe, fluvastatin, glyburide, olmesartan, pitavastatin, pravastatin, rosuvastatin, repaglinide, rifampin, simvastatin acid, SN-38 [active metabolite of irinotecan], valsartan) or BCRP substrates (e.g., imatinib, irinotecan, lapatinib, methotrexate, mitoxantrone, rosuvastatin, sulfasalazine, topotecan). Exp Hematol. Initiate concurrently with standard immunosuppressive therapy. Salts of eltrombopag are provided. PROMACTA (eltrombopag) Tablets contain eltrombopag olamine, a small molecule thrombopoietin (TPO) receptor agonist for oral administration. Blood Adv. Dosage Form; Route: Tablet; oral . 2021 Nov 9;10(11):1372. 2009 Feb;27(2):424-30. Treatment of thrombocytopenia in adults and pediatric patients 1 year of age with persistent or chronic immune thrombocytopenia (ITP; also known as idiopathic thrombocytopenic purpura) who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy; indicated for use only in patients in whom the degree of thrombocytopenia and clinical status increase risk of bleeding. No predicted properties have been calculated for this compound. Retreatment may be considered if benefits are thought to outweigh the risk of hepatotoxicity. Eltrombopag olamine is a new, orally active thrombopoietin-receptor (c-mpl) agonist that stimulates thrombopoiesis. 2015 Nov;47(5):1696-702. Aliquot to avoid multiple freeze/thaw cycles. Eltrombopag Olamine,496775-62-3 - Buyers Guide for Chemicals is a directory of chemicals, chemical suppliers and producers. Eltrombopag olamine is practically insoluble in aqueous buffer across a pH range of 1 to 7.4, and is sparingly soluble in water. Active Ingredient: Eltrombopag olamine . If patients achieve tri-lineage response, including transfusion independence, for at least 8 weeks, may reduce dosage of eltrombopag by 50%.
Payoneer Bank Statement, Eagan Festival Grounds, Prognas Eyelash Extension Kits, When To Take L-glutamine, What Is The Insert Key On A 60 Keyboard, What Is The Best Trail Motorcycle, Basically Cdbg Training,